特瑞普利单抗免疫相关不良事件药学监护

doi:10.19803/j.1672-8629.20230428

中国药物警戒 ›› 2024, Vol. 21 ›› Issue (3): 346-348.
DOI: 10.19803/j.1672-8629.20230428

特瑞普利单抗免疫相关不良事件药学监护

吉秋霞^1,2, 金剑², 章斌^2,*

¹海安市人民医院药剂科,江苏南通226600;
²上海交通大学附属第九人民医院药剂科,上海 200011

收稿日期:2023-07-07 出版日期:2024-03-15 发布日期:2024-03-18
通讯作者: ^*章斌,女,硕士,主管药师,临床药学。
作者简介:吉秋霞,女,硕士,副主任药师,临床药学。

Pharmaceutical care for immune-related adverse events induced by toripalimab

JI Qiuxia^1,2, JIN Jian², ZHANG Bin^2,*

¹Department of Pharmacy, Hai’an Hospital Affiliated to Nantong University, Nantong Jiangsu 226001, China;
²Department of Pharmacy, Shanghai Ninth People’S Hospital, Shanghai Jiao tong University, School of Medicine, Shanghai 200011, China;

Received:2023-07-07 Online:2024-03-15 Published:2024-03-18

摘要/Abstract

摘要： 目的探讨临床药师在特瑞普利单抗引起的免疫相关不良事件中的药学监护方式。方法临床药师对1例患者使用特瑞普利单抗治疗后查出肾损伤、甲状腺功能减退及骨骼肌毒性的病例进行药学查房,通过不良反应关联性评价和机制分析,判断该患者很可能是由特瑞普利单抗引起的不良反应。结果临床药师协助医生制定治疗方案、并对患者进行了全程化药学监护,取得良好效果。结论临床药师在免疫相关不良事件的识别和管理中发挥重要作用,有效保障患者用药安全。

关键词: 特瑞普利单抗, 肾损伤, 甲状腺功能减退, 骨骼肌毒性, 横纹肌溶解症, 药品不良反应, 药学监护

Abstract: Objective To explore the pharmaceutical care approach of clinical pharmacists in immune-related adverse events caused by toripalimab. Methods A clinical pharmacist conducted a pharmacy checkup on a case in which renal injury, hypothyroidism and skeletal muscle toxicity were detected in a patient treated with toripalimab, and determined that the patient was most likely to have adverse reactions caused by toripalimab through the evaluation of the correlation of the adverse reactions and the analysis of the mechanism. Results A clinical pharmacist assisted the physician in formulating the treatment plan, and conducted full-scale pharmacological monitoring of the patient, achieving good results. Conclusion Clinical pharmacists play an important role in the identification and management of immune-related adverse events, effectively ensure the safety of medication.

Key words: toripalimab, renal injury, hypothyroidism, skeletal muscle toxicity, rhabdomyolysis, adverse drug reaction(ADR), pharmaceutical care

中图分类号:

R994.11

吉秋霞, 金剑, 章斌. 特瑞普利单抗免疫相关不良事件药学监护[J]. 中国药物警戒, 2024, 21(3): 346-348.

JI Qiuxia, JIN Jian, ZHANG Bin. Pharmaceutical care for immune-related adverse events induced by toripalimab[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 346-348.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.zgywjj.com/CN/10.19803/j.1672-8629.20230428

https://www.zgywjj.com/CN/Y2024/V21/I3/346

参考文献

[1] CHOW LQM, HADDAD R, GUPTA S, et al.Antitumor activity of pembolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib keynote-012 expansion cohort[J]. J Clin Oncol, 2016, 34(32): 3838-3845.
[2] ZHANG L, HAO B, GENG Z, et al.Toripalimab: the first domestic anti-tumor PD-1 antibody in China[J]. Front Immunol, 2022 (1): 730666.
[3] WU Q, ZHANG S, HUA X, et al.Complete and enduring response in an elderly patient with repeated recurrent gingival squamous cell carcinoma treated by combined toripalimab and single agent chemotherapy: a case report[J]. Ann Palliat Med, 2021, 10(6): 6968-6973.
[4] BARAIBAR I, MELERO I, PONZ-SARVISE M, et al.Safety and tolerability of immune checkpoint inhibitors (PD-1 and PD-L1) in cancer[J]. Drug Saf, 2019, 42(2): 281-294.
[5] WANG ND, DING ZY, ZHAO QC, et al.Pharmaceutical monitoring of a patient with multiple immune-related adverse events after treatment with triprilizumab[J]. Practical Pharmacy & Clinical Remedies(实用药物与临床), 2023, 26(3): 233-236.
[6] CHEN Y, CHEN Y, XIE J, et al.Multisystem immune-related adverse events due to toripalimab: Two cases-based review[J]. Front Cardiovasc Med, 2022, 9(11): 1036603.
[7] KODA R, WATANABE H, TRUCHIDA M, et al.Immune checkpoint inhibitor(nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis:A case report[J]. BMC Nephrol, 2018, 19(1): 48.
[8] SHIMAMURA Y, WATANABE S, MAEDA T, et al . Incidence and risk factors of acute kidney injury, and its effect on mortality among Japanese patients receiving immune check point inhibitors: A single-center observational study[J]. Clinical and Experimental Nephrology, 2021, 25(5): 479-487.
[9] LI L, LI G, RAO B, et al.Landscape of immune checkpoint inhibitor-related adverse events in Chinese population[J]. Scientific Reports, 2020, 10(1): 15567.
[10] MORGANSTEIN DL,LAI Z,SPAIN L,et al.Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treat-ment of melanoma[J]. Clin Endocrinol (Oxf), 2017, 86(4): 614-602.
[11] JOHNSON DB, BALKO JM, COMPTON ML, et al.Fulminant myocarditis with combination immune checkpoint blockade[J]. N Engl J Med, 2016, 375(18): 1749-1755.
[12] HUANG L.The analysis of clinical characteristics in 30 patients with hypothyroidism and muscular damage[D]. Jinan: Shandong University,2017.
[13] Guidelines Working Committee of Chinese Society of Clinical Oncology. Chinese Society of Clinical Oncology (CSCO) immune checkpoint inhibitor-related toxicity management guidelines[中国临床肿瘤学会(CSCO) 免疫检查点抑制剂相关的毒性管理指南] [M]. Beijing: People’s Medical Publishing House, 2019.
[14] Chinese Society of Endocrinology. Guidelines for the diagnosis and treatment of hypothyroidism in adults[J]. Chinese Journal of Endocrinology and Metabolism(中华内分泌代谢杂志),2017,33(2): 167-180.
[15] Immune-endocrinology Group, Chinese Society of Endocrinology Chinese Medical Association.Chinese expert consensus on the immune checkpoint inhibitors-induced endocrine immune-related adverse events(2020)[J]. Chinese Journal of Endocrinology and Metabolism(中华内分泌代谢杂志),2021, 37(1): 1-16.
[16] GU SL.The effect and mechanism on regeneration and repair in renal tubular epithelial cell after injury by the inhibitory proliferation effect of ACEI and ARB[D]. Fuzhou: Fujian Medical University, 2014.
[17] Chinese Society of Nephrology, Renal Diseases Committee of the Chinese. Society of Integrative Medicine. Guidelines for the management of renal hypertension in China 2016[J]. Chinese Society of Nephrology, 2017, 97(20): 1547-1555.
[18] LI YD.Treatment of diabetic nephropathy with calcitriol: A Meta-analysis[D]. Changchun: Jilin University, 2017.
[19] MOREIRA A, LOQUAI C, PFÖHLER C, et al. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors[J]. Eur J Cancer, 2019, 106(1): 12-23.
[20] SZNOL M, POSTOW MA, DAVIES MJ, et al.Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management[J]. Cancer Treat Rev, 2017, 58(7): 70-76.
[21] WANG XM, WANG WJ, WANG XH, et al.Application of the patient report form about Immune-related adverse events in the treatment of pd-1 inhibitors[J]. Clinical Journal of Traditional Chinese Medicine(中医药临床杂志), 2020, 32(1): 159-163.

特瑞普利单抗免疫相关不良事件药学监护

Pharmaceutical care for immune-related adverse events induced by toripalimab

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	杨波, 王梦娇, 胡丽丽, 王来成, 李倩, 孔飞飞, 吕冬梅, 沈佳妮. 385例PD-1抗肿瘤治疗的安全性研究及风险因素分析[J]. 中国药物警戒, 2024, 21(4): 447-450.
[2]	黎海燕, 杨忠旭, 刘跃昆, 王丽虹. 1例甲氨蝶呤治疗异位妊娠致严重不良反应患者的药学监护[J]. 中国药物警戒, 2024, 21(4): 454-456.
[3]	李少强, 孔旭东, 李朋梅. 注射用奥美拉唑钠致低钠血症1例分析[J]. 中国药物警戒, 2024, 21(4): 461-463.
[4]	伍诗琪, 闫素英, 张青霞. 艾多沙班药代动力学相互作用研究进展[J]. 中国药物警戒, 2024, 21(4): 473-480.
[5]	黄焕均, 麦嘉恒, 张云惠, 郭晨晨, 梁蔚婷. 613例抗肿瘤药物的不良反应分析[J]. 中国药物警戒, 2024, 21(3): 324-328.
[6]	陈杰, 张斌, 赵俊, 张传洲. 托珠单抗注射液致过敏性休克1例分析[J]. 中国药物警戒, 2024, 21(3): 349-351.
[7]	杨雪婷, 何波, 闫鸿丽, 李冬梅. 克拉霉素致急性短暂性抑郁症不良反应1例分析[J]. 中国药物警戒, 2024, 21(3): 352-354.
[8]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[9]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[10]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[11]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[12]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[13]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[14]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[15]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.